Comparison
Carbetocin vs. LL-37
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
37025-55-1
597562-32-8
Molecular weight
no data
4493.33 g/mol
Half-life
0.67 h
no data
Sequence
no data
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESMechanism of action
Carbetocin
Carbetocin is an oxytocin receptor agonist with prolonged duration. It triggers a sustained contraction of the uterus after birth, preventing atonic hemorrhage — unlike oxytocin, without a multi-hour infusion.
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
1
4
of which in humans
1
1
Effects recorded
2
4
Open conflicts
0
1
Documented adverse events
1
0
Legal status
Full entries
Frequently asked questions
- What is the difference between Carbetocin and LL-37?
- Carbetocin is classified as "Research other", while LL-37 is classified as "Research other". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Carbetocin or LL-37?
- The highest available evidence level is "Human RCT" for Carbetocin and "Human trial" for LL-37. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Carbetocin and LL-37 in Germany and the United States?
- Germany: Carbetocin — Prescription, LL-37 — Research only. United States: Carbetocin — Unapproved, LL-37 — Research only. These are factual summaries with source and review date on the individual pages.